• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Zentek Provides Market Update on ZenGUARD(TM) Antimicrobial Surgical Masks

    10/17/24 8:00:00 AM ET
    $HSIC
    $ZTEK
    Medical Specialities
    Health Care
    Major Chemicals
    Industrials
    Get the next $HSIC alert in real time by email

    GUELPH, ON / ACCESSWIRE / October 17, 2024 / Zentek Ltd. ("Zentek" or the "Company") (NASDAQ:ZTEK)(TSXV:ZEN), an intellectual property development and commercialization company, is pleased to provide an update on recent commercialization activities for its ZenGUARD™Antimicrobial Surgical Masks.

    As previously announced on July 24, 2024, the Company embarked on a Canada-wide sampling program for dental professionals facilitated by Henry Schein Inc. ("Henry Schein") that saw ZenGUARD™ Antimicrobial Surgical Masks included in product shipments to Henry Schein customers across Canada. As a result of this program and the unique value proposition ZenGUARD™ Antimicrobial Surgical Masks bring to dental practitioners and their patients, the Company is now seeing increased demand from Henry Schein. Henry Schein (NASDAQ:HSIC) is the world's largest provider of health care solutions to office-based dental and medical practitioners with a presence in 33 countries.

    Zentek continues to explore opportunities in other markets including in the beauty space and in international healthcare and dental markets where demand for surgical masks is expected to be more stable long term.

    As previously announced on April 24, 2024, the Company applied to the Food and Drug Administration (FDA) for authorization to market and sell its ZenGUARD™ Surgical Masks in the United States. The FDA has requested additional information regarding ZenGUARD™ and the Company is currently evaluating the additional information requests.

    "In addition to better protection against infectious agents, ZenGUARD™ Antimicrobial Surgical Masks are also proven to eliminate 99.9% of bacteria, which can collect on the skin when wearing a surgical mask for extended periods and cause acne. We believe this unique value proposition will continue to drive increased demand in the dental market and is a very natural fit for the beauty industry as well. We look forward to continuing to build on the recent success generated in the Henry Schein sampling program and to expanding the platform globally." said Greg Fenton, Zentek CEO.

    About Zentek Ltd.

    Zentek is an ISO 13485:2016 certified intellectual property technology company focused on the research, development and commercialization of novel products seeking to give the Company's commercial partners a competitive advantage by making their products better, safer, and greener.

    Zentek's patented technology platform ZenGUARD™, is shown to have 99-per-cent antimicrobial activity and to significantly increase the viral filtration efficiency for surgical masks and aims to do the same for HVAC (heating, ventilation, and air conditioning) systems. Zentek's ZenGUARD™ production facility is in Guelph, Ontario.

    For further information on Zentek:

    [email protected]

    Ryan Shacklock
    Senior VP, Strategy & Business Development
    Email: [email protected]
    Phone: 306-270-9610

    To find out more about Zentek, please visit our website at www.Zentek.com. A copy of this news release and all material documents in respect of the Company may be obtained on Zentek's SEDAR+ profile at http://www.sedarplus.ca/.

    Forward-Looking Statements

    This news release contains forward-looking statements. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although Zentek believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Zentek disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

    Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

    SOURCE: Zentek Ltd.



    View the original press release on accesswire.com

    Get the next $HSIC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Q&A

    New
    • What recent developments have been reported regarding Zentek's ZenGUARD™ Surgical Masks?

      Zentek Ltd. has reported an increase in demand for their ZenGUARD™ Antimicrobial Surgical Masks, particularly through a sampling program for dental professionals facilitated by Henry Schein Inc.

    • In addition to the dental market, what other markets is Zentek exploring for their surgical masks?

      Zentek is exploring opportunities in various markets, especially the beauty space and international healthcare and dental markets that show stable long-term demand for surgical masks.

    • What is the current status of Zentek's FDA application for ZenGUARD™ Surgical Masks?

      The FDA has requested additional information from Zentek regarding their application to market and sell ZenGUARD™ Surgical Masks in the United States, which is currently being evaluated by the Company.

    • What unique benefits do ZenGUARD™ Surgical Masks offer beyond protection from infectious agents?

      ZenGUARD™ Antimicrobial Surgical Masks are claimed to eliminate 99.9% of bacteria that can cause acne, making them not just protective but also beneficial for the skin.

    • What are Zentek's expectations for the future following the success of their recent sampling program?

      The Company is optimistic about its growth and global expansion plans, especially following the success from the Henry Schein sampling program.

    Recent Analyst Ratings for
    $HSIC
    $ZTEK

    CompanyDatePrice TargetRatingAnalyst
    Henry Schein Inc.
    $HSIC
    2/23/2026$100.00Neutral → Outperform
    Robert W. Baird
    Henry Schein Inc.
    $HSIC
    12/9/2025$86.00Overweight
    Barclays
    Henry Schein Inc.
    $HSIC
    8/26/2025$83.00In-line → Outperform
    Evercore ISI
    Henry Schein Inc.
    $HSIC
    7/25/2025$75.00Buy → Hold
    Stifel
    Henry Schein Inc.
    $HSIC
    7/14/2025$72.00Outperform → Neutral
    Robert W. Baird
    Henry Schein Inc.
    $HSIC
    2/14/2025$80.00Equal Weight
    Wells Fargo
    Henry Schein Inc.
    $HSIC
    1/6/2025$69.00 → $84.00Underperform → Buy
    BofA Securities
    Henry Schein Inc.
    $HSIC
    12/4/2024$75.00Neutral
    Mizuho
    More analyst ratings

    $HSIC
    $ZTEK
    SEC Filings

    View All

    SEC Form 6-K filed by Zentek Ltd.

    6-K - Zentek Ltd. (0001904501) (Filer)

    3/9/26 4:55:20 PM ET
    $ZTEK
    Major Chemicals
    Industrials

    SEC Form 6-K filed by Zentek Ltd.

    6-K - Zentek Ltd. (0001904501) (Filer)

    3/4/26 10:50:24 AM ET
    $ZTEK
    Major Chemicals
    Industrials

    SEC Form 6-K filed by Zentek Ltd.

    6-K - Zentek Ltd. (0001904501) (Filer)

    2/26/26 5:19:17 PM ET
    $ZTEK
    Major Chemicals
    Industrials

    $HSIC
    $ZTEK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Daniel William K bought $670,800 worth of shares (10,000 units at $67.08) (SEC Form 4)

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    8/11/25 4:26:33 PM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    $ZTEK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Henry Schein One Unveils the Next Era of Dentrix Ascend for DSOs and Growth-Focused Practices

    New Packages Accelerate Revenue Through an Integrated, Agentic Platform Henry Schein One, the market leader in dental practice management systems, today unveiled the next era of Dentrix Ascend—introducing three new packages built on a fully integrated, agentic platform architecture designed to help practices and Dental Service Organizations (DSOs) increase revenue and accelerate growth. The new offering strengthens Dentrix Ascend's position as the platform of choice for modern dental organizations while advancing Henry Schein One's strategy to unify practice management, clinical workflows, imaging, and revenue cycle management within a single intelligent platform. Momentum behind Dent

    3/10/26 6:30:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein to Participate in Upcoming Investor Conferences in March

    Henry Schein, Inc., the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that the Company will present at the following conferences in March: Leerink's Global Healthcare Conference at the W South Beach hotel, Miami, on March 9, at 10:00 a.m. EST. Barclays 28th Annual Global Healthcare Conference at the Loews Miami Beach hotel, Miami, on March 10, at 10:30 a.m. EST. Henry Schein's presentations can be heard via live webcast by visiting www.henryschein.com/IRwebcasts. Replays will be available on the Henry Schein website following the presentations. About Henry Schein, Inc. Henry Schein, Inc. (NASDAQ:HSIC) is a so

    3/3/26 6:30:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Biomerica Reports Real-World Data: Nearly 60% of IBS Patients Achieved Clinically Meaningful Pain Reduction and 68% Achieved Bloating Reduction with the inFoods® IBS Therapy

    Key Highlights Responder Analysis: 59.4% of patients achieved ≥30% reduction in abdominal pain; 68.1% achieved ≥30% reduction in bloating—using the FDA-recognized responder endpoint consistent with the Company's peer-reviewed randomized controlled trial.CMS Payment Rate: $300 national Medicare payment rate established, effective January 1, 2026.Physician Perspective: New interview with Gastroenterologist Dr. Dak Patel about inFoods IBS in clinical use now available at https://investors.biomerica.com/events-and-presentations/default.aspx IRVINE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), an innovator in diagnostic-guided therapy, today announced respo

    2/26/26 8:19:00 AM ET
    $BMRA
    $HSIC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Medical Specialities

    $HSIC
    $ZTEK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Henry Schein upgraded by Robert W. Baird with a new price target

    Robert W. Baird upgraded Henry Schein from Neutral to Outperform and set a new price target of $100.00

    2/23/26 8:29:17 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Barclays initiated coverage on Henry Schein with a new price target

    Barclays initiated coverage of Henry Schein with a rating of Overweight and set a new price target of $86.00

    12/9/25 8:50:15 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein upgraded by Evercore ISI with a new price target

    Evercore ISI upgraded Henry Schein from In-line to Outperform and set a new price target of $83.00

    8/26/25 8:13:41 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    $ZTEK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Large owner Kkr Hawaii Aggregator L.P.

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    3/10/26 5:15:14 PM ET
    $HSIC
    Medical Specialities
    Health Care

    SEC Form 4 filed by Henry Schein Inc.

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    3/10/26 5:10:49 PM ET
    $HSIC
    Medical Specialities
    Health Care

    SVP, Chief Human Res. Officer Sheehy Christine Zayac was granted 7,087 shares, increasing direct ownership by 60% to 18,917 units (SEC Form 4)

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    3/10/26 5:06:51 PM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    $ZTEK
    Leadership Updates

    Live Leadership Updates

    View All

    Henry Schein Enters Exclusive Distribution Agreement for CytoChip's CLIA-Waived Hematology Analyzer

    Partnership Expands Access to FDA-Cleared CitoCBC® System Across the U.S. Henry Schein, Inc. (NASDAQ:HSIC) has entered into a new exclusive distribution agreement with CytoChip Inc. for its flagship product, the CitoCBC® system, a U.S. Food and Drug Administration (FDA) 510(k)-cleared device. Available now to Henry Schein customers in the United States, the CitoCBC system is the first cartridge-based Complete Blood Count (CBC) system to receive a CLIA Waiver, helping expand access to accurate, lab-quality testing at the point of care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115495488/en/CLIA Waived CitoCBC System Des

    1/15/26 10:00:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Names Frederick M. Lowery as Chief Executive Officer

    Industry veteran brings more than 20 years of healthcare distribution experience and operational excellence Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of healthcare solutions to office-based dental and medical professionals, today announced the appointment of Frederick M. Lowery as its new Chief Executive Officer ("CEO"), effective March 2, 2026, at which time he will join the Board of Directors. Mr. Lowery succeeds Stanley M. Bergman, who will step down as CEO after 35 years and continue to serve as Chairman of the Board to ensure a smooth and effective leadership transition. This press release features multimedia. View the full release here: https://www.businesswire

    1/12/26 7:00:00 AM ET
    $HSIC
    $TMO
    Medical Specialities
    Health Care
    Industrial Machinery/Components
    Industrials

    Stanley M. Bergman to Retire as Henry Schein's Chief Executive Officer at the End of 2025

    Mr. Bergman to Continue to Serve as Chairman of the Board Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that Stanley M. Bergman will retire as Chief Executive Officer (CEO) at the end of the year after 45 years at the Company, including more than 35 years as CEO. Mr. Bergman will continue to lead Henry Schein in his current role until his retirement and will remain as Chairman thereafter. The Board is commencing a formal search process in conjunction with a nationally recognized executive search firm and will consider internal and external candidates. "With the progress made advan

    7/15/25 7:05:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    $ZTEK
    Financials

    Live finance-specific insights

    View All

    Henry Schein Reports Fourth Quarter and Full Year 2025 Financial Results and Introduces 2026 Financial Guidance

    Q4 2025 GAAP diluted EPS of $0.85, compared to $0.74 GAAP diluted EPS in Q4 2024 Q4 2025 non-GAAP diluted EPS of $1.34, compared to $1.19 non-GAAP diluted EPS in Q4 2024 2026 non-GAAP diluted EPS expected to be in the range of $5.23 to $5.37, with total sales growth expected to be 3-5% Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the fourth quarter ended December 27, 2025. "Our fourth-quarter sales reflect continuing momentum resulting in the highest sales growth in 15 quarters. We are pleased with the sales results across all our businesses, particul

    2/24/26 6:00:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein to Webcast Fourth Quarter 2025 Conference Call on Tuesday, February 24, 2026, at 8:00 A.M. ET

    Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of healthcare solutions to office-based dental and medical practitioners, announced today that it will release its fourth quarter 2025 financial results before the stock market opens on Tuesday, February 24, 2026, and will provide a live webcast of its earnings conference call on the same day beginning at 8:00 a.m. Eastern time. Speakers on the call will include Stanley M. Bergman, Chairman of the Board and Chief Executive Officer, and Ronald N. South, Senior Vice President and Chief Financial Officer. Investors can access the call by visiting https://investor.henryschein.com/webcasts. A replay will be available on the Henry S

    1/22/26 6:30:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Reports Record Third Quarter 2025 Financial Results and Raises Full Year Non-GAAP EPS Guidance

    Q3 2025 GAAP diluted EPS of $0.84, compared to $0.78 GAAP diluted EPS in Q3 2024, and Q3 2025 non-GAAP diluted EPS of $1.38, compared to $1.22 non-GAAP diluted EPS in Q3 2024 Raises 2025 guidance for non-GAAP diluted EPS to $4.88 to $4.96 and sales growth to 3-4% to reflect third quarter results Announces value creation initiatives expected to deliver over $200 million of operating income improvement over the next few years Agreement reached to provide KKR the right to increase its HSIC stock ownership up to 19.9% Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results

    11/4/25 6:00:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    $ZTEK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Henry Schein Inc.

    SC 13G/A - HENRY SCHEIN INC (0001000228) (Subject)

    11/13/24 3:30:01 PM ET
    $HSIC
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Henry Schein Inc.

    SC 13G - HENRY SCHEIN INC (0001000228) (Subject)

    11/12/24 9:32:27 AM ET
    $HSIC
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Henry Schein Inc. (Amendment)

    SC 13G/A - HENRY SCHEIN INC (0001000228) (Subject)

    2/14/24 11:18:57 AM ET
    $HSIC
    Medical Specialities
    Health Care